Seclidemstat (SP-2577) (Synonyms: SP-2577) |
| Catalog No.GC32820 |
Seclidemstat (SP-2577) is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat (SP-2577) promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat (SP-2577) can be used for the research of Ewing Sarcoma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1423715-37-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Seclidemstat (SP-2577) is a potent LSD1 inhibitor, with a mean IC50 of 127 nM.
Seclidemstat (Compound 2577) reduces tumor volume at 40, 80 mg/kg by i.p. and also shows such effect at 80 mg/kg via p.o. dosing.
[1]. SUBSTITUTED BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIBITORS. WO/2017/004519 A1
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *